MMED (Minimed Group) YoY EBITDA Growth: -181.43% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MMED Minimed Group Inc MMED
15 GF Score
Price $19.86
! 3 Warning Signs
View Full Analysis

What is Minimed Group YoY EBITDA Growth?

Minimed Group MMED +1.82% 15 YoY EBITDA Growth is -181.43% as of Apr. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Minimed Group's YoY EBITDA Growth for the quarter that ended in Apr. 2026 was -181.43%.

Minimed Group's EBITDA per Share for the three months ended in Apr. 2026 was $-0.17.

Minimed Group YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Minimed Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group YoY EBITDA Growth Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25 Apr26
YoY EBITDA Growth
0.00 47.56 159.09 -101.91

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26 Apr26
YoY EBITDA Growth Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -181.43
MMED
15GF Score
Minimed Group Inc MMED
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Minimed Group's YoY EBITDA Growth for the fiscal year that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (A: Apr. 2026 )
=(EBITDA per Share (A: Apr. 2026 )-EBITDA per Share (A: Apr. 2025 ))/ | EBITDA per Share (A: Apr. 2025 ) |
=(-0.012-0.627)/ | 0.627 |
=-101.91 %

Minimed Group's YoY EBITDA Growth for the quarter that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (Q: Apr. 2026 )
=(EBITDA per Share (Q: Apr. 2026 )-EBITDA per Share (Q: Jan. 2025 )) / | EBITDA per Share (Q: Jan. 2025 )) |
=(-0.171-0.21)/ | 0.21 |
=-181.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -181.43% mean?
Minimed Group (MMED) has a YoY EBITDA Growth of -181.43% as of Apr. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Minimed Group and its competitors.
Is Minimed Group's YoY EBITDA Growth too high?
Minimed Group's current YoY EBITDA Growth is -181.43%. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's YoY EBITDA Growth compare to MMSI and NVST?
Minimed Group's YoY EBITDA Growth of -181.43% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Minimed Group and its competitors. Minimed Group's current YoY EBITDA Growth is -181.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current YoY EBITDA Growth of -181.43%. The current YoY EBITDA Growth is -181.43%. Minimed Group's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Minimed Group (MMED), the current YoY EBITDA Growth is -181.43% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges B8S:Germany
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score

Get the complete analysis for MMED

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.86
Price